AVGR - アビンガ― （Avinger Inc.） アビンガ―AVGRのチャート
AVGRの企業情報
| symbol | AVGR |
|---|---|
| 会社名 | Avinger Inc （アビンガ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 Avinger Inc. is a commercial-stage medical device company. The Company designs manufactures and sells image-guided catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and certain European markets. The Company''s products include Lightbox imaging console as well as its Wildcat Kittycat and the Ocelot family of catheters which are designed to allow physicians to penetrate a total blockage in an artery known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products including Ocelot Ocelot PIXL Ocelot MVRX and Pantheris. アビンガ―は、米国の医療機器会社。末梢動脈疾患（PAD）の治療のため、医者によって使われるカテ―テルベ―スのシステムを設計、製造、販売する。米国および選ばれた欧州市場で一連の製品を製造、販売。同社の製品は、ライトボックス・イメ―ジング・コンソ―ルやカテ―テルのワイルドキャット、キティキャット、オスロットシリ―ズなど。 Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye™ family of chronic total occlusion (CTO) catheters, and the Pantheris® line of atherectomy devices. Avinger is based in Redwood City, California. |
| 本社所在地 | 400 Chesapeake Drive Redwood City CA 94063 USA |
| 代表者氏名 | Jeffrey M. Soinski ジェフリーM.ソンスキー |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-363-2400 |
| 設立年月日 | 39142 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2015年 |
| 従業員数 | － |
| url | www.avinger.com |
| nasdaq_url | https://www.nasdaq.com/symbol/avgr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -24.91300 |
| 終値（lastsale） | 1.22 |
| 時価総額（marketcap） | 14093503.44 |
| 時価総額 | 時価総額（百万ドル） 13.40038 |
| 売上高 | 売上高（百万ドル） 7.85100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 11.07938 |
| 当期純利益 | 当期純利益（百万ドル） -43.13500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Avinger Inc revenues decreased 35% to $3.9M. Net loss applicable to common stockholders decreased 20% to $22.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Selling general and administrative decrease of 46% to $7.5M (expense) Research and development - Balancing decrease of 54% to $2.7M (expense). |
AVGRのテクニカル分析
AVGRのニュース
Avinger Q1 Earnings Preview 2023/05/09 21:35:50 Seeking Alpha
Avinger (AVGR) is scheduled to announce Q1 earnings results on Wednesday, May 10th, after market close.The consensus EPS Estimate is -$0.49 and the consensus Revenue Estimate is $2M…
Avinger, Inc.: Avinger to Announce First Quarter 2023 Results on May 10 2023/05/02 12:02:00 Finanz Nachrichten
REDWOOD CITY, CA / ACCESSWIRE / May 2, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system f…
Avinger to Announce First Quarter 2023 Results on May 10 2023/05/02 12:00:00 Wallstreet:Online
REDWOOD CITY, CA / ACCESSWIRE / May 2, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, …
Avinger, Inc.: Leading Data on the Treatment of In-Stent Restenosis with Pantheris Presented at Charing Cross International Symposium 2023/04/28 12:02:00 Finanz Nachrichten
REDWOOD CITY, CA / ACCESSWIRE / April 28, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based syste…
Leading Data on the Treatment of In-Stent Restenosis with Pantheris Presented at Charing Cross International Symposium 2023/04/28 12:00:00 Accesswire
REDWOOD CITY, CA / ACCESSWIRE / April 28, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the presentation of clinical data from the INSIGHT study during the Charing Cross (CX) International Symposium in London, England. The CX Symposium is a leading vascular and endovascular education conference focused on education, innovation, and evidence. The INSIGHT trial was designed to evaluate the safety and effectiveness of Avinger''s Pantheris image-guided atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries. Dr. Arne Schwindt, a vascular surgeon and endovascular interventionist in one of Germany''s leading endovascular centers at St. Franziskus Hospital in Münster, presented 6 and 12-month follow-up results in his presentation entitled "Treatment of In-stent Restenosis with an Atherectomy Catheter: Results from the INSIGHT Study." Data from the study supported the subsequent 510(k) clearance by the U.S.
Avinger, Inc (AVGR) Q3 2022 Earnings Call Transcript 2022/11/13 17:11:02 Seeking Alpha
Start Time: 16:30 End Time: 16:50 Avinger, Inc (NASDAQ:NASDAQ:AVGR) Q3 2022 Earnings Conference Call November 09, 2022, 16:30 PM ET Company Participants Jeff Soinski - CEO Nabeel Subainati…
Avinger GAAP EPS of -$0.77, revenue of $2.25M 2022/11/09 21:32:31 Seeking Alpha
Avinger press release (AVGR): Q3 GAAP EPS of -$0.77.Revenue of $2.25M (-5.1% Y/Y).Gross margin of 35%, with increased revenue and capital sales driving a 4-percentage point…
Avinger Announces Issuance of Seven New Patents Expanding Coverage for Its Proprietary Image-Guided Atherectomy Devices 2022/11/04 12:00:00 Accesswire
REDWOOD CITY, CA / ACCESSWIRE / November 4, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the issuance of seven new U.S. and international patents in the second and third quarters of 2022 and provided an update on the expansion of its intellectual property portfolio. The seven new patents expand intellectual property protection for Avinger''s proprietary image-guided atherectomy systems. In the second and third quarters of 2022, Avinger has been granted four (4) issued U.S. patents, two (2) issued European patents and one (1) issued Japanese patent, including: U.S. patent 11,399,863, Atherectomy Catheter with Serrated Cutter U.S. patent 11,344,327, Catheter Device with Detachable Distal End U.S. patent 11,406,412, Atherectomy Catheters with Imaging U.S. patent 11,382,653, Atherectomy Catheter . Avinger has increased its patent portfolio significantly in 2022, with 8 new patents issued or allowed in the U.S. and 8 new patents issued or allowed in international markets.
Why Rogers Shares Are Trading Sharply Lower; Here Are 33 Stocks Moving Premarket 2022/11/02 11:58:58 Benzinga
Gainers Avinger, Inc. (NASDAQ: AVGR ) rose 32% to $1.36 in pre-market trading. Avinger is expected to release its financial results for the third quarter on Wednesday, November 9, 2022. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) shares rose 28.8% to $23.55 in pre-market trading. Arcturus reported collaboration with CSL to develop and commercialize self-amplifying mRNA vaccines. Code Chain New Continent Limited (NASDAQ: CCNC ) rose 23.2% to $0.1770 in pre-market trading after declining 7% on Tuesday. Baudax Bio, Inc. (NASDAQ: BXRX ) rose 20.3% to $0.2388 in pre-market trading. Chegg, Inc. (NYSE: CHGG ) rose 19.1% to $25.14 in pre-market trading after the company reported better-than-expected Q3 results. The company also issued FY22 sales guidance above analyst estimates. Scopus BioPharma Inc. (NASDAQ: SCPS ) rose 19% to $0.2988 in pre-market trading. Match Group, Inc. (NASDAQ: MTCH ) shares rose 16.2% to $51.00 in pre-market trading after the company reported better-than-expected Q3 results.
Astonishing stocks: Verastem, Inc. (NASDAQ:VSTM 1.68%), Avinger, Inc. (NASDAQ:AVGR -0.71%) 2022/09/16 00:14:48 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Astonishing stocks: Verastem, Inc. (NASDAQ:VSTM 1.68%), Avinger, Inc. (NASDAQ:AVGR -0.71%) appeared first on Stocks Equity .
Avinger to Announce First Quarter 2022 Results on May 10 2022/04/29 13:00:00 Wallstreet:Online
REDWOOD CITY, CA / ACCESSWIRE / April 29, 2022 / Avinger, Inc. (Nasdaq:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery …
Avinger stock climbs premarket on launch of Lightbox 3 imaging console 2022/04/19 12:52:34 Seeking Alpha
Avinger (AVGR) stock climbed 11.2% premarket on Tuesday after the medical device maker announced the full commercial launch of its Lightbox 3 imaging console.AVGR conducted a…
AXSM, BTAI and AVGR among pre market gainers 2022/04/19 12:30:59 Seeking Alpha
Checkmate Pharmaceuticals CMPI +332% Regeneron to acquire Checkmate Pharma in $250 million all-cash deal.Axsome Therapeutics (AXSM) +27%
Avinger Announces Full Commercial Launch of Lightbox 3 2022/04/19 12:00:00 Wallstreet:Online
REDWOOD CITY, CA / ACCESSWIRE / April 19, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of …
Atherectomy Devices Market Size is Anticipated to Progress at a Significant CAGR of 9.24% During the Study Period, Assesses DelveInsight 2022/04/11 17:00:00 Benzinga
New York, USA, April 11, 2022 (GLOBE NEWSWIRE) -- Atherectomy Devices Market Size is Anticipated to Progress at a Significant CAGR of 9.24% During the Study Period, Assesses DelveInsight The Atherectomy Devices market size is expected to boost due to several factors such as rising geriatric population, rising prevalence of cardiovascular diseases, growing prevalence of lifestyle disorders such as hypertension and diabetes, and innovation in product development, among others. DelveInsight''s Atherectomy Devices Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Atherectomy Devices companies in the market. Key Takeaways from the Atherectomy Devices Market Report According to DelveInsight analysis, North America is anticipated to dominate the global Atherectomy Devices market during the forecast period. The leading Atherectomy Devices companies with various types of Atherectomy Devices in various stages of development such as Koninklijke Philips N.V., Medtronic, Boston Scientific Corporation, AngioDynamics Inc, Cardiovascular Systems Inc, Avinger, BD, Ra Medical Systems, REX Medical , and others are currently working in the Atherectomy Devices market.